CoChat

Weight loss in MASLD restores the balance of liver fatty acid sources

Open access
Lambert, Jennifer E., Ramos-Roman, Maria A., Valdez, Maressa J., Browning, Jeffrey D., Rogers, Thomas, Parks, Elizabeth J. · 2025 · Journal of Clinical Investigation

The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Lipogenesis contributes substantially to the pathological accumulation of intrahepatic triacylglycerol (IHTG) in metabolic dysfunction–associated steatotic liver disease (MASLD). Since hepatic lipogenesis is highly sensitive to energy intake, we hypothesized that mechanisms of MASLD regression induced by weight loss would be driven by a marked reduction in the lipogenic pathway. METHODS: Overweight adults with high liver fat (HighLF; n = 9; IHTG ≥ 5.6% measured by 1 H-magnetic resonance spectroscopy) or low (normal) liver fat (LowLF; n = 6; IHTG < 5.6%) received dietary counseling for 6 months and underwent comprehensive metabolic phenotyping during inpatient studies that captured fasting and fed states. Multiple stable isotopes were used to assess the contribution of lipogenesis, free fatty acids (FFAs), and dietary fat to IHTG. RESULTS: Body weight loss (–10% ± 2%) reduced IHTG in individuals with MASLD (19.4% ± 3.6% to 4.5% ± 2.1%, P < 0.001). Insulin sensitivity improved significantly (46%, P < 0.01), while fasting FFA flux from adipose tissue was not different. VLDL-triacylglycerol (VLDL-TG) concentrations fell by 38% ( P = 0.02) because of a 67% reduction in contribution from lipogenesis ( P = 0.02), whereas the absolute contributions from FFAs and dietary fat to VLDL-TG were not different. Reduced lipogenesis was significantly associated with loss of IHTG. CONCLUSION: These data underscore the primary role of lipogenesis in MASLD pathology and highlight the importance of controlling this pathway through treatment strategies. TRIAL REGISTRATION: ClinicalTrials.gov (NCT01371396). FUNDING: National Institutes of Health (NIH) grant RL1DK081187; Task Force for Obesity Research at Southwestern (TORS) NIH UL1DE019584; and Clinical and Translational Science Award NIH/National Center for Advancing Translational Sciences UL1-RR024982.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci174233

Cites

67 of 67 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Six-month study design and inpatient protocol to quantitate fatty acid and TG metabolism. (A) Subjects were recruited to participate in a 6-month dietary study to determine the metabolic mechanisms of weight loss–induced improvements in liver fat, including insulin metabolism (assessed in admission 1 via a frequently sampled, insulin-modified i.v. glucose tolerance test) and fatty acid metabolism. (B) Before and after weight loss, fatty acid metabolism was measured during an overnight isotope infusion study. Oral dosing with deuterated water occurred for 10 days before the inpatient study, and fatty acid isotopes were incorporated into the evening meal and infused i.v. to track adipose FFA flux and the sources of VLDL-TG palmitate. Data from the 24-hour study were analyzed to assess post-meal lipid metabolism, nighttime flux of lipids, and how these processes changed when the subjects fasted an additional 4 hours, followed by a meal. CTRC, Clinical and Translational Research Center; FFA, free fatty acids.
Figure 1 Six-month study design and inpatient protocol to quantitate fatty acid and TG metabolism. (A) Subjects were recruited to participate in a 6-month dietary study to determine the metabolic mechanisms of weight loss–induced improvements in liver fat, including insulin metabolism (assessed in admission 1 via a frequently sampled, insulin-modified i.v. glucose tolerance test) and fatty acid metabolism. (B) Before and after weight loss, fatty acid metabolism was measured during an overnight isotope infusion study. Oral dosing with deuterated water occurred for 10 days before the inpatient study, and fatty acid isotopes were incorporated into the evening meal and infused i.v. to track adipose FFA flux and the sources of VLDL-TG palmitate. Data from the 24-hour study were analyzed to assess post-meal lipid metabolism, nighttime flux of lipids, and how these processes changed when the subjects fasted an additional 4 hours, followed by a meal. CTRC, Clinical and Translational Research Center; FFA, free fatty acids.CC BY · PubMed Central
Figure 2 Weight loss and its impact on liver fat. (A) Weight loss trajectories of subjects with low liver fat (LowLF; n = 6) and high liver fat (HighLF; n = 9) over the 6-month dietary intervention; data are mean ± SEM. (B) Changes in liver fat measured by MRS. Change in liver fat between the groups due to weight loss was assessed by 2-way repeated-measures ANOVA.
Figure 2 Weight loss and its impact on liver fat. (A) Weight loss trajectories of subjects with low liver fat (LowLF; n = 6) and high liver fat (HighLF; n = 9) over the 6-month dietary intervention; data are mean ± SEM. (B) Changes in liver fat measured by MRS. Change in liver fat between the groups due to weight loss was assessed by 2-way repeated-measures ANOVA.CC BY · PubMed Central
Figure 3 Plasma glucose, insulin, FFA, and TG levels after dinner, at night, and after an extended fast and lunch, before and after weight loss. Data are mean ± SEM for LowLF (n = 6) and HighLF (n = 9) for plasma levels of glucose (A and B), insulin (C and D), FFAs (E and F), and TGs (G and H). P values denoted on the graphs represent main effect of weight loss analyzed by 3-way RM-ANOVA for changes in metabolites by (i) time over the 24-hour testing period, (ii) weight loss, and (iii) liver fat group, with subgroup comparisons conducted for within-group changes after weight loss at each time point. *Time points significantly different after weight loss within a group.
Figure 3 Plasma glucose, insulin, FFA, and TG levels after dinner, at night, and after an extended fast and lunch, before and after weight loss. Data are mean ± SEM for LowLF (n = 6) and HighLF (n = 9) for plasma levels of glucose (A and B), insulin (C and D), FFAs (E and F), and TGs (G and H). P values denoted on the graphs represent main effect of weight loss analyzed by 3-way RM-ANOVA for changes in metabolites by (i) time over the 24-hour testing period, (ii) weight loss, and (iii) liver fat group, with subgroup comparisons conducted for within-group changes after weight loss at each time point. *Time points significantly different after weight loss within a group.CC BY · PubMed Central
Figure 4 Glucose and fat oxidation in the fasting and fed states before and after weight loss. Respiratory gas analysis was conducted in the fasting and fed states to assess changes in glucose (A) and fat (B) oxidation. Three-way RM-ANOVA was used to assess the effects of (i) transitioning from fasting to fed states, (ii) weight loss, and (iii) liver fat group on changes in glucose and fat oxidation. P values above the graphs reflect main effects of fasting to fed state, weight loss, or liver fat group, and interaction effects of these. P values on the graphs represent change from fasting to fed state assessed through subgroup comparisons in the 3-way RM-ANOVA. Data are from LowLF and HighLF subjects showing the mean (indicated by “+”; may be behind a data point); boxes represent the 25th and 75th percentiles; middle line in the boxes represents the median; and whiskers represent the minimum and maximum values. One LowLF subject at baseline and one HighLF subject at follow-up had missing data (due to equipment malfunction), and therefore LowLF n = 5 and HighLF n = 8 for both fat and glucose oxidation measurements.
Figure 4 Glucose and fat oxidation in the fasting and fed states before and after weight loss. Respiratory gas analysis was conducted in the fasting and fed states to assess changes in glucose (A) and fat (B) oxidation. Three-way RM-ANOVA was used to assess the effects of (i) transitioning from fasting to fed states, (ii) weight loss, and (iii) liver fat group on changes in glucose and fat oxidation. P values above the graphs reflect main effects of fasting to fed state, weight loss, or liver fat group, and interaction effects of these. P values on the graphs represent change from fasting to fed state assessed through subgroup comparisons in the 3-way RM-ANOVA. Data are from LowLF and HighLF subjects showing the mean (indicated by “+”; may be behind a data point); boxes represent the 25th and 75th percentiles; middle line in the boxes represents the median; and whiskers represent the minimum and maximum values. One LowLF subject at baseline and one HighLF subject at follow-up had missing data (due to equipment malfunction), and therefore LowLF n = 5 and HighLF n = 8 for both fat and glucose oxidation measurements.CC BY · PubMed Central
Figure 5 Plasma turnover of adipose-derived FFAs and labeled palmitate appearing in VLDL-TG based on the palmitate source before and after weight loss in LowLF and HighLF subjects. Isotopic labeling of the FFA pool was initiated at midnight. The rate of appearance of plasma FFAs (RaFFA; A and B) and proportions of VLDL-TG palmitate derived from the 3 sources (dinner meal, C and D; plasma FFA pool, E and F; and DNL, G and H) are presented from midnight onward. For the reader’s interest, the changes in proportional contributions of fatty acid sources after lunch are presented, but because this is not a system in steady state, statistical analysis of changes in sources (as well as RaFFA, for consistency) after lunch (1200 hours) was not performed. Therefore, P values on the graph represent main effect of weight loss analyzed by 3-way RM-ANOVA for changes in RaFFA and sources of VLDL-TG palmitate by (i) time over the 12-hour testing period (midnight to 1200 only), (ii) weight loss, and (iii) liver fat group, with subgroup comparisons for within-group changes after weight loss at each time point. Data are mean ± SEM for LowLF (n = 6) and HighLF (n = 9). *Time points significantly different within a group after weight loss.
Figure 5 Plasma turnover of adipose-derived FFAs and labeled palmitate appearing in VLDL-TG based on the palmitate source before and after weight loss in LowLF and HighLF subjects. Isotopic labeling of the FFA pool was initiated at midnight. The rate of appearance of plasma FFAs (RaFFA; A and B) and proportions of VLDL-TG palmitate derived from the 3 sources (dinner meal, C and D; plasma FFA pool, E and F; and DNL, G and H) are presented from midnight onward. For the reader’s interest, the changes in proportional contributions of fatty acid sources after lunch are presented, but because this is not a system in steady state, statistical analysis of changes in sources (as well as RaFFA, for consistency) after lunch (1200 hours) was not performed. Therefore, P values on the graph represent main effect of weight loss analyzed by 3-way RM-ANOVA for changes in RaFFA and sources of VLDL-TG palmitate by (i) time over the 12-hour testing period (midnight to 1200 only), (ii) weight loss, and (iii) liver fat group, with subgroup comparisons for within-group changes after weight loss at each time point. Data are mean ± SEM for LowLF (n = 6) and HighLF (n = 9). *Time points significantly different within a group after weight loss.CC BY · PubMed Central
Figure 6 Six routes of palmitate entry into hepatic VLDL-TG assembly. (A) Data are means, with variances removed for clarity, for LowLF (n= 6) and HighLF (n = 9). (B) Individual data points are shown with the mean (indicated by “+”; may be behind a data point); boxes represent the 25th and 75th percentiles; middle line in the boxes represents the median; and whiskers represent the minimum and maximum values. At the end of the fasting period (before the lunch meal), sources of palmitate were quantitated as a proportion found in VLDL-TG. Proportional contributions reflect the contribution of fatty acid sources being used within the liver at the site(s) of intracellular-TG synthesis as reflected in VLDL. A portion of VLDL-TG is synthesized from stored intrahepatic lipid that does not become labeled during the course of isotope administration (gray bars). Changes due to weight loss were assessed between the groups using 2-way RM-ANOVA. There were main effects of weight loss (P < 0.001) and liver fat group (P = 0.025) for proportion of VLDL-TG palmitate derived from FFAs as well as for DNL (weight loss P = 0.001 and liver fat group P = 0.041). P values above the bar graphs in A show differences between the 2 groups at baseline (assessed by unpaired 2-tailed t test). P values next to the bars in A represent baseline versus follow-up comparisons within a single group (assessed by paired 2-tailed t test); these within-group comparisons are reiterated above the bars in B.
Figure 6 Six routes of palmitate entry into hepatic VLDL-TG assembly. (A) Data are means, with variances removed for clarity, for LowLF (n= 6) and HighLF (n = 9). (B) Individual data points are shown with the mean (indicated by “+”; may be behind a data point); boxes represent the 25th and 75th percentiles; middle line in the boxes represents the median; and whiskers represent the minimum and maximum values. At the end of the fasting period (before the lunch meal), sources of palmitate were quantitated as a proportion found in VLDL-TG. Proportional contributions reflect the contribution of fatty acid sources being used within the liver at the site(s) of intracellular-TG synthesis as reflected in VLDL. A portion of VLDL-TG is synthesized from stored intrahepatic lipid that does not become labeled during the course of isotope administration (gray bars). Changes due to weight loss were assessed between the groups using 2-way RM-ANOVA. There were main effects of weight loss (P < 0.001) and liver fat group (P = 0.025) for proportion of VLDL-TG palmitate derived from FFAs as well as for DNL (weight loss P = 0.001 and liver fat group P = 0.041). P values above the bar graphs in A show differences between the 2 groups at baseline (assessed by unpaired 2-tailed t test). P values next to the bars in A represent baseline versus follow-up comparisons within a single group (assessed by paired 2-tailed t test); these within-group comparisons are reiterated above the bars in B.CC BY · PubMed Central
Figure 7 VLDL-TG concentrations and turnover rates before and after weight loss. Data are from LowLF subjects (n = 6 for A and n = 5 for B–D because of missing data for 1 subject that precluded kinetic analysis) and HighLF subjects (n = 9) and show impacts of weight loss. (A) Reduction of fasting VLDL-TG concentrations. (B) No changes in VLDL-TG production rates. (C) Increase in fractional catabolic rates. (D) Modest effect on particle-TG clearance rate. Data are presented as mean (indicated by “+” on the graph; may be behind a data point); boxes represent the 25th and 75th percentiles; middle line in the boxes represents the median; and whiskers represent the minimum and maximum values. P values above the graphs indicate main effects of weight loss and liver fat group determined by 2-way RM-ANOVA; no interaction effects were observed. P values on the graphs represent subgroup comparisons from the 2-way RM-ANOVA in the change from baseline to follow-up within LowLF and HighLF groups.
Figure 7 VLDL-TG concentrations and turnover rates before and after weight loss. Data are from LowLF subjects (n = 6 for A and n = 5 for B–D because of missing data for 1 subject that precluded kinetic analysis) and HighLF subjects (n = 9) and show impacts of weight loss. (A) Reduction of fasting VLDL-TG concentrations. (B) No changes in VLDL-TG production rates. (C) Increase in fractional catabolic rates. (D) Modest effect on particle-TG clearance rate. Data are presented as mean (indicated by “+” on the graph; may be behind a data point); boxes represent the 25th and 75th percentiles; middle line in the boxes represents the median; and whiskers represent the minimum and maximum values. P values above the graphs indicate main effects of weight loss and liver fat group determined by 2-way RM-ANOVA; no interaction effects were observed. P values on the graphs represent subgroup comparisons from the 2-way RM-ANOVA in the change from baseline to follow-up within LowLF and HighLF groups.CC BY · PubMed Central
Figure 8 Relationships between changes in liver fat and reductions in VLDL-TG, insulin sensitivity, and lipogenesis. (A) Arrows depict the magnitude of absolute changes in liver fat and plasma VLDL-TG concentrations for HighLF (n = 9) and LowLF (n = 6) subjects. (B) For all subjects combined, the greater the improvements in insulin sensitivity (assessed by the insulin sensitivity index via the i.v. glucose tolerance test), the greater the reductions in fasting VLDL-TG palmitate %DNL (assessed by Pearson’s correlation). For the HighLF subjects, stepwise regression coefficients are presented for predictors of the absolute (Abs) change in IHTG with weight loss (C), and for predictors of the final level of IHTG at follow-up (D). For example, in C, large reductions in IHTG (follow-up minus baseline) were predicted by greater baseline IHTG levels and greater increases in insulin sensitivity.
Figure 8 Relationships between changes in liver fat and reductions in VLDL-TG, insulin sensitivity, and lipogenesis. (A) Arrows depict the magnitude of absolute changes in liver fat and plasma VLDL-TG concentrations for HighLF (n = 9) and LowLF (n = 6) subjects. (B) For all subjects combined, the greater the improvements in insulin sensitivity (assessed by the insulin sensitivity index via the i.v. glucose tolerance test), the greater the reductions in fasting VLDL-TG palmitate %DNL (assessed by Pearson’s correlation). For the HighLF subjects, stepwise regression coefficients are presented for predictors of the absolute (Abs) change in IHTG with weight loss (C), and for predictors of the final level of IHTG at follow-up (D). For example, in C, large reductions in IHTG (follow-up minus baseline) were predicted by greater baseline IHTG levels and greater increases in insulin sensitivity.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 67 references

Cited by

See all 20

Metadata

Authors
Lambert, J. E., Ramos-Roman, M. A., Valdez, M. J., Browning, J. D., Rogers, T., & Parks, E. J.
Affiliations
  • Center for Human Nutrition,
  • Department of Internal Medicine,
  • Department of Clinical Nutrition, and
  • The University of Texas Southwestern Medical Center (US)
Corresponding author
Parks, Elizabeth J.
Venue
Journal of Clinical Investigation
Published
2025-05-01
Volume
135
Issue
9
ISSN
  • 0021-9738 (ISSN-L)
  • 1558-8238
OpenAlex
W4410004319
Cited by
20
References
67
Citations by year
2026: 14 · 2025: 6
FWCI
13.75
Type
journal article
Language
en
Open access
Locations
  • Journal of Clinical Investigation (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
National Institutes of Health (RL1DK081187, NIH UL1DE019584, NIH/NCATS UL1-RR024982)
Topics
  • Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Lipid metabolism and biosynthesis
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diet, Metabolism, and Disease
Keywords
non-alcoholic fatty liver disease, weight loss, hepatic lipogenesis, free fatty acids, dietary fat, insulin sensitivity, caloric restriction
MeSH terms
Adult, Fatty Acids, Nonesterified, Fatty Liver, Female, Humans, Insulin Resistance, Liver, Male, Middle Aged, Triglycerides, Weight Loss, Lipogenesis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Weight loss in MASLD restores the balance of liver fatty acid sources. https://app.cochat.ai/papers/10.1172/jci174233
The paper
Lambert, J. E., Ramos-Roman, M. A., Valdez, M. J., Browning, J. D., Rogers, T., & Parks, E. J. (2025). Weight loss in MASLD restores the balance of liver fatty acid sources. Journal of Clinical Investigation. https://doi.org/10.1172/jci174233

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.